ESPR (Esperion Therapeutics) Other Gross PPE: $3.0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ESPR Esperion Therapeutics Inc ESPR
41 GF Score
Price $3.18
GF Value $2.28
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Esperion Therapeutics Other Gross PPE?

Esperion Therapeutics ESPR -0.31% 41 Other Gross PPE is $3.0 Mil as of Mar. 2026. GuruFocus rates ESPR with a GF Score™ of 41/100 and a GF Value™ of $2.28 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Esperion Therapeutics's Other Gross PPE for the quarter that ended in Mar. 2026 was $3.0 Mil.

Esperion Therapeutics's quarterly Other Gross PPE declined from Sep. 2025 ($3.5 Mil) to Dec. 2025 ($3.1 Mil) and declined from Dec. 2025 ($3.1 Mil) to Mar. 2026 ($3.0 Mil).

Esperion Therapeutics's annual Other Gross PPE increased from Dec. 2023 ($4.9 Mil) to Dec. 2024 ($5.7 Mil) but then declined from Dec. 2024 ($5.7 Mil) to Dec. 2025 ($3.1 Mil).

Esperion Therapeutics Other Gross PPE Historical Data

* Premium members only.

The historical data trend for Esperion Therapeutics's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Esperion Therapeutics Other Gross PPE Chart

Esperion Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Gross PPE
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.20 1.34 4.86 5.70 3.11

Esperion Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Gross PPE Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.20 4.43 3.50 3.11 3.01
ESPR
41GF Score
Esperion Therapeutics Inc ESPR
Other Gross PPE is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Esperion Therapeutics Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.

Frequently Asked Questions Learn more about Other Gross PPE →
What does a Other Gross PPE of $3.0 Mil mean?
Esperion Therapeutics (ESPR) has a Other Gross PPE of $3.0 Mil as of Mar. 2026. Other Gross PPE is property, plant and equipment recorded on a company's balance sheet that not otherwise classified. View historical data on Esperion Therapeutics and its competitors.
Is Esperion Therapeutics' Other Gross PPE too high?
Esperion Therapeutics' current Other Gross PPE is $3.0 Mil. Overall, Esperion Therapeutics has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Esperion Therapeutics' Other Gross PPE compare to AMPH and NIKA?
Esperion Therapeutics' Other Gross PPE of $3.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Gross PPE for a Drug Manufacturers company?
A good Other Gross PPE depends on the Drug Manufacturers industry context. However, Other Gross PPE should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Gross PPE mean?
A high Other Gross PPE can signal that a stock is expensive relative to its fundamentals. Other Gross PPE is property, plant and equipment recorded on a company's balance sheet that not otherwise classified. View historical data on Esperion Therapeutics and its competitors. Esperion Therapeutics's current Other Gross PPE is $3.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Esperion Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Esperion Therapeutics (ESPR) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.28, compared to a current price of $3.18 — trading 39.5% above its estimated fair value. The current Other Gross PPE is $3.0 Mil. Esperion Therapeutics' overall GF Score™ is 41/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Gross PPE calculated?
Other Gross PPE is calculated from a company's financial statements. For Esperion Therapeutics (ESPR), the current Other Gross PPE is $3.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Esperion Therapeutics (ESPR) Overvalued in 2026?

Based on GuruFocus' analysis, Esperion Therapeutics stock appears to be overvalued. The current stock price of $3.18 is trading 39.5% above its estimated GF Value™ of $2.28. GuruFocus considers Esperion Therapeutics to be Significantly Overvalued.

Key valuation signals for ESPR:

  • Other Gross PPE: $3.0 Mil
  • GF Value™: $2.28 vs. price of $3.18 (39.5% above fair value)
  • GF Score™: 41/100 with 6 warning signs

No single metric tells the full story. See the ESPR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Esperion Therapeutics Business Description

Other Exchanges 0IIM:UK0ET:Germany
Address 3891 Ranchero Drive, Suite 150, Ann Arbor, MI, USA, 48108
Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.
41GF Score

Get the complete analysis for ESPR

Other Gross PPE is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.18
Price
$2.28
GF Value